Oral ER-Targeting Therapies in ER+, HER2: Metastatic Breast Cancer

Dr. Wander explores the evolving role of oral ER-targeting treatments for patients with ESR1-mutant, ER+, HER2– metastatic breast cancer. Data from key clinical trials is discussed, and the implications of utilizing oral ER-targeting therapies in clinical practice are explored.

Topics covered:

• Address unmet needs in ESR1-mutant, ER+, HER2– MBC following progression on CDK4/6 inhibitor-based therapy.
• Explore ER-targeting combination therapies from pivotal clinical trials, including EMBER-3 (imlunestrant plus abemaciclib), SERENA-6 (camizestrant plus a CDK4/6 inhibitor), and evERA (giredestrant plus everolimus).
• Review clinical implications and patient selection factors for ER-targeting therapy.

CDK4/6=cyclin-dependent kinase 4 and 6; ER= estrogen receptor; ESR1= estrogen receptor 1; HER2=human epidermal growth factor receptor 2; MBC= metastatic breast cancer.